Slide 1: Prof. Rob Phillips, Chairman and CEO, Uscom Limited
For personal use only Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia July 14th 2020 Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia
Slide 2: CEO message on record growth
For personal use only “ Uscom delivers record growth in a rapidly shrinking commercial world. Medical technology is a cornerstone of health and investment, and Uscom continues to execute a targeted global strategy of growth and expansion. While the future is uncertain, China, Uscom’s major market, i
Slide 3: The Uscom Mission
THE USCOM MISSION For personal use only Ambitious and growth driven RAP© Uscom – The Measure of Life
Slide 4: Results – Record Year
RESULTS – RECORD YEAR For personal use only 1. Record annual cash receipts $4.6M (up 36%), revenue and sales 2. Record annual net cash flow up $2.07M and debt free 3. Record H2 – First profitable and cash flow positive half 4. Record H2 – Cash receipts $3.02M (up 84%), Sales $2.87 (up 64%) 5. Record
Slide 5: UCM Cash Receipts
For personal use only UCM Cash Receipts $5.00 $4.60 ASX:UCM ↑ 36% $4.00 ➢ Record Cash Receipts and $3.50 $3.39 Sales $2.94 $3.00 $2.90 ➢ Growth Trend Continues $M AUD ➢ Cash Receipts $4.6M up 36% $2.04 $2.00 ➢ H2 Profitable $1.38 ➢ Cash on Hand $1.01 $0.86 $1.00 ➢ Debt Free $0.00 2012 2013 2014 2015
Slide 6: UCM Annual Results
For personal use only UCM Annual Results 5.00 ↑ 36% 4.6 4.00 ↑ 29% ASX:UCM 3.65 3.39 3.00 2.84 ➢ Record results ➢ Cash receipts $4.6M up 36% 2.00 ➢ Sales $3.65M up 29% $M AUD FY 19 ↑ $2.07M FY 20 ➢ Net cash flow up $2.07M 1.00 0.78 ↑ $0.04M ➢ Poor H1 due to global 0.00 restructure, with record H2 Pr
Slide 7: UCM H2
For personal use only UCM H2 3.50 ↑ 84% ↑ 62% 3.02 ASX:UCM 3.00 2.87 2.50 ➢ Record H2 Results 2.00 1.78 ➢ Cash receipts $3.02M up 84% 1.64 1.50 ➢ Sales revenue $2.87M up 62% ↑ $1.47M $M AUD 1.00 2019 ➢ Net cash flow up $1.47M ↑ $0.78M 2020 0.50 0.50 ➢ Profit up $0.78M 0.14 ➢ Profitable, cash flow po
Slide 8: UCM 4C Q4
UCM 4C Q4 For personal use only ↑ 57% 2.00 1.92 1.50 ↑27% ASX:UCM 1.21 ↑ $0.06M 1.00 ➢ Record Q4 results 1.00 0.87 0.81 0.79 ➢ Cash receipts $1.00M up 27% ➢ Sales revenue $0.87M up 7% $M AUD FY 19 0.50 FY 20 ➢ Net Cash flow up $0.10M ↑ $0.10M ➢ Cash on hand up 57% 0.00 Net Cash Sales Cash Cash on ➢
Slide 9: Innovation
INNOVATION For personal use only Uscom technology Uscom Digital Spirometry provides the highest quality personal spirometers allowing U l t r a s o n i c F l o w Te c h n o l o g y home lung function testing at research standards. “FOR MEDICAL TECHNOLOGY COMPANIES INNOVATION DETERMINES FUTURE REVENU
Slide 10: Introducing New Product
For personal use only Introducing New Product
Slide 11: New Product - VentiTest
NEW PRODUCT - VENTITEST For personal use only VentiTest is a multi-path ultrasonic ventilator test device with PC based display and analytics designed for pressure, flow and volume testing and calibration of ventilator outputs. Uscom is increasing manufacture and marketing of VENTITEST Hospital Depa
Slide 12: Growing Global
GROWING GLOBAL For personal use only • London • Beijing • Budapest • LA Operations Sydney Beijing Budapest • Singapore Offices Singapore Auckland • Sydney London • Auckland LA Multiple products hedged for currencies and markets RAP©
Slide 13: 2021 Growth Drivers
2021 GROWTH DRIVERS For personal use only VENTITEST – Uscom ventilator calibration BP+ and SpiroSonic approvals due for China and US Europe and US up-grading and increasing infectious disease centres New European and US distribution models Uscom China growing - numbers and quality of distributors Ch
Slide 14: 2021 Risks
2021 Risks For personal use only Regulatory Travel limitation approvals become impairs global trade protection management Global disorder and Compliance slow economic overload – cost, recovery intervention and inefficiency
Slide 15: UCM – Tightly Held
UCM – TIGHTLY HELD For personal use only Shareholding Quality growth stock NED Invested management CEO Strong strategic vision Ex CEO Investor 1 Record growth in fundamentals Free Float Investor 2a 31% Investor 2b Investor 3 ~150M FPO UCM shares on issue Distributor ~35±10c (Current price 22c) Inves
Slide 16: Results
RESULTS For personal use only 01 Record Cash Receipts $4.6M up 36% with cash on hand China Strong and Rebounding 02 Expanding operations and recovering activity and orders China strong and rebounding 03 H2 – Profitable cash flow positive, debt free 04 Europe Expanding sales activity increasing 05 Ne
Slide 17: Conclusion
For personal use only CONCLUSION “ 2020 was a year of record financial results with profit and cash flow positivity and rapid growth in the second half following global restructure and Uscom China establishment. Investment in China and all major markets is planned to deliver continuing growth with n
Slide 18: Prof. Rob Phillips contact
For personal use only Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia July 14th 2020 Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia
Slide 19: Corporate Social Responsibility
Corporate Social Responsibility For personal use only Winning the battle against Cape York’s feral pigs